The AT 1 -Type Angiotensin Receptor in Oxidative Stress and Atherogenesis
2002; Lippincott Williams & Wilkins; Volume: 105; Issue: 3 Linguagem: Inglês
10.1161/hc0302.102618
ISSN1524-4539
AutoresGeorg Nickenig, David G. Harrison,
Tópico(s)Sodium Intake and Health
ResumoHomeCirculationVol. 105, No. 3The AT1-Type Angiotensin Receptor in Oxidative Stress and Atherogenesis Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessOtherPDF/EPUBThe AT1-Type Angiotensin Receptor in Oxidative Stress and AtherogenesisPart I: Oxidative Stress and Atherogenesis Georg Nickenig, MD and David G. Harrison, MD Georg NickenigGeorg Nickenig From Klinik und Poliklinik Innere Medizin III (G.N.), Universität des Saarlandes, Homburg/Saar, Germany; and the Department of Medicine (D.G.H.), Division of Cardiology, Medical School of Emory University, Atlanta, Ga. and David G. HarrisonDavid G. Harrison From Klinik und Poliklinik Innere Medizin III (G.N.), Universität des Saarlandes, Homburg/Saar, Germany; and the Department of Medicine (D.G.H.), Division of Cardiology, Medical School of Emory University, Atlanta, Ga. Originally published22 Jan 2002https://doi.org/10.1161/hc0302.102618Circulation. 2002;105:393–396Angiotensin II, the principal effector of the renin angiotensin system, is a multifunctional peptide that modulates blood pressure, water and sodium homeostasis, neuronal function, and other neurohumoral systems.1–3 Initial research with angiotensin II focused on its role in the pathogenesis of hypertension; however, in the past decade, increasing evidence has accumulated to indicate that this octapeptide is involved in the development of atherosclerosis, myocardial infarction, vascular and myocardial remodeling, and congestive heart failure.4–7 The effects of angiotensin II are mediated by 2 plasma membrane receptors, referred to as the AT1 and AT2 subtypes.3,4 In adult tissues, the AT2 receptor is predominantly expressed in the brain and adrenals, with lower levels expressed elsewhere.8 AT2 receptor stimulation leads to vasodilatation and inhibition of vascular smooth muscle growth. During embryogenesis, the AT2 receptor is expressed in developing arteries, and seems to play a role in curbing vascular smooth muscle growth and guiding the ultimate thickness of the vascular wall.8,9 Although interesting and important roles of the AT2 receptor continue to be defined, most of the known functions of angiotensin II are related to AT1 receptor activation. AT1 receptors belong to the 7-membrane–domain superfamily of G-protein–coupled receptors and are expressed in vascular smooth muscle cells, heart, lung, brain, liver, kidney, and adrenal glands.3 AT1 receptors are coupled to a variety of intracellular signaling molecules, including the phospholipases A2, C, and D, adenylate cyclase, voltage-dependent Ca2+ channels, and to a variety of kinases involved in phosphorylation cascades.2–4 Depending on the cell and organ type, stimulation of these signal transduction pathways leads to cellular contraction, hypertrophy, proliferation, and/or apoptosis.2–4,10,11 During the past few years, it has become apparent that one of the most important consequences of AT1 receptor activation, particularly in the cardiovascular system, is the production and release of reactive oxygen species.12,13AT1 Receptor and Oxidative StressDuring normal cellular metabolism, several enzyme systems reduce molecular oxygen, resulting in formation of a variety of reactive oxygen species, including superoxide (O2·−), hydroxyl radical (HO·), hypochlorous acid (HOCl), lipid radicals, and hydrogen peroxide (H2O2).14,15 Reactive oxygen species likely play a critical role in the normal functioning of cells. For example, the normal growth of vascular smooth muscle cells seems to require reactive oxygen species.16 An excessive production of reactive oxygen species, outstripping antioxidant defense systems, has been referred to as oxidant stress and has been implicated in many pathophysiological conditions in the cardiovascular system, including cigarette smoking, hypercholesterolemia, diabetes, hypertension, and heart failure.17 There are several untoward events that occur as a consequence of oxidant stress. These include oxidative modifications of DNA, lipid oxidation, modification of proteins, and activation of redox sensitive genes.18 Redox-sensitive genes are important in cardiovascular disease because many of these, such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and monocyte chemoattractant protein-1 (MCP-1) are proinflammatory and play a critical role in the initiation and progression of atherosclerosis.19–21 Another significant consequence of reactive oxygen species is modification of enzyme function. An excellent example of this is the activation of matrix metalloproteinases (MMPs). These enzymes play a key role in allowing any cell to grow or migrate and are crucial in both vascular and myocardial remodeling.22–24There is a broad body of evidence that AT1 receptor activation leads to production of reactive oxygen species in the vessel wall, in part because the AT1 receptor is linked to activation of an NADH/NADPH oxidase in vascular cells.25 This oxidase system, which has similarities to the neutrophil oxidase, is a major source of reactive oxygen species in endothelial cells, vascular smooth muscle cells, and adventitial fibroblasts.26 Endothelial cells contain all of the subunits of the neutrophil oxidase, including gp91phox, p47phox, p67phox, p22phox, and the small GTPase rac1. In contrast, vascular smooth muscle cells contain a recently discovered protein termed NOX (for nonphagocytic oxidase), which seems to replace gp91phox as one of the membrane components.27 How the various subunits interact in vascular cells and how they produce superoxide is not well understood. It is clear, however, that the vascular NAD(P)H oxidase is responsive to hormones, metabolic factors, and mechanical forces.26,28 Besides growth factors and cytokines, angiotensin II is a principal activator of NAD(P)H oxidase expressed in vascular smooth muscle cells and fibroblasts.25,26 Angiotensin II activates the NAD(P)H oxidase via AT1 receptor activation through stimulation of intracellular signaling pathways such as arachidonic acid metabolites.29 Furthermore, angiotensin II induces a rapid translocation of the small GTPase rac1 to the cellular membrane, a prerequisite of NAD(P)H oxidase activation.30 Besides these rapid effects, angiotensin II exerts long-term alterations by enhancing the gene expression of rac1, p22phox, and NOX-1.25–27,30The NADPH oxidase is probably not the only source of reactive oxygen species stimulated by angiotensin II. Recently, it has become apparent that endothelial nitric oxide synthase (eNOS) can produce large amounts of superoxide under certain pathophysiological conditions.31,32 One mechanism for this relates to oxidative destruction of tetrahydrobiopterin, which is a critical cofactor for eNOS function.33–35 In the absence of tetrahydrobiopterin, eNOS transfers electrons to molecular oxygen rather than to l-arginine resulting in superoxide production. Recent studies have suggested that any condition that increases superoxide production (so called "kindling radicals") in the endothelium may ultimately lead to production of a large amount of superoxide ("bonfire radicals") from uncoupled eNOS.36Endogenous reactive oxygen species stimulated by activation of the AT1 receptor play critical roles as intracellular signaling molecules. Of the many reactive oxygen species generated in mammalian cells, hydrogen peroxide seems particularly important in cell signaling. Hydrogen peroxide is relatively stable and uncharged, allowing it to diffuse from one cell to the next. Numerous intracellular targets for hydrogen peroxide and other reactive oxygen species have been described, including the mitogen-activated protein kinase (MAPK) family, the cell survival kinase Akt, ras/rac, c-src, protein kinase C, and tyrosine phosphatases. Reactive oxygen species also modulate intracellular Ca2+ levels, altering numerous early signaling events. Many of these events have also been show to be downstream of AT1 receptor activation and are known to be redox-sensitive signaling targets.37–41Interactions Between the AT1 Receptor, the Nitric Oxide Pathway, and AtherogenesisOne of the important consequences of increased superoxide production in response to angiotensin II is inactivation of nitric oxide.17 The two radicals superoxide and nitric oxide react with one another at a rate of 6.7×109 mol/L−1 · s−1, resulting in formation of peroxynitrite.14,15,17 Generally, the endogenous superoxide dismutases and other scavengers of superoxide keep this reaction to a minimum; however, when cellular levels of superoxide are increased, for example on angiotensin II stimulation, this reaction proceeds.42 Loss of nitric oxide via this mechanism leads to endothelial dysfunction, one of the earliest steps in the atherosclerotic process. Numerous cell culture, animal model, and clinical studies have supported the concept that AT1 receptor activation causes vascular superoxide release in vitro and in vivo leading to impaired endothelium-dependent vasodilation.25,43 In concert with these findings, inhibition of AT1 receptor activation by AT1 receptor antagonists or ACE inhibitors improves endothelial dysfunction.44–46 Loss of nitric oxide and formation of peroxynitrite promote atherosclerosis at virtually all stages of the disease.17 The earliest stages of atherosclerosis disease are associated with increased attraction and adhesion of monocytes to the endothelium.5 Inflammatory molecules such MCP-1 and VCAM-1 are critically important in this process. Importantly, expression of these is redox-sensitive and inhibited by nitric oxide.19–21,47 Angiotensin II seems to induce their production and secretion via generation of reactive oxygen species and suppression of nitric oxide.Another phase of the atherosclerotic process is fatty streak formation, which is characterized by increased oxidation of LDL, uptake of oxLDL by macrophages, and foam cell formation, processes that are promoted by AT1 receptor activation.5,48,49 Of note, it has recently been demonstrated that expression of a receptor for oxidized LDL, known as the LOX receptor, is dramatically increased by AT1 receptor activation.48 In addition, oxLDL uptake may be also enhanced via angiotensin II effects on the cellular proteoglycan content.49Plaque formation is propagated by migration and proliferation of vascular smooth muscle cells. Again, there is ample evidence suggesting that the oxidant stress induced by angiotensin II plays a major role in stimulating growth and migration of vascular smooth muscle cells.5,17Finally, plaque rupture is the result of increased lipid deposition, inflammatory events, apoptosis, and accelerated matrix degradation within the preformed vascular lesion.5 Besides the enhanced lipid deposition, AT1 receptor activation initiates inflammatory processes such as interleukin-6 production.50 Vascular smooth muscle cell apoptosis, which seems to be a prelude to plaque rupture, is induced via angiotensin II and prevented by AT1 receptor blockade.10,11 In keeping with these observations, angiotensin II increases MMP activity, resulting in plaque degradation and ultimately rupture.24 Interestingly, recent reports have suggested that angiotensin II modulates hematopoiesis within the bone marrow. Monocyte CD11b expression is enhanced, ultimately impacting on monocyte-endothelial interactions.7 To date, it is not clear whether endothelial dysfunction during early atherogenesis resembles the pathological state of endothelial cells shortly before or during plaque rupture. Within this review, both syndromes are referred to as endothelial dysfunction.To summarize the above information, angiotensin II, via its actions on the AT1 receptor, promotes the atherosclerotic process at virtually all stages of the disease (Figure 1). These actions of angiotensin II are at least in part mediated by reactive oxygen species. Download figureDownload PowerPointAT1 receptor–induced oxidative stress and atherosclerosis. AT1 receptor activation leads to the release of reactive oxygen species in various vascular cells. Oxidative stress is in turn involved in monocyte attraction and activation. This involves increased production of monocyte chemoattractant protein-1 (MCP-1). In endothelial cells, adhesion molecules that are essential for the adhesion of monocytes, such as intercellular adhesion molecule-1 (ICAM-1) and the vascular adhesion molecule-1 (VCAM-1), are induced by angiotensin II via superoxide anions. In vascular smooth muscle cells (VSMCs), numerous biological processes are induced by reactive oxygen species. AT1 receptor activation increases expression of the oxLDL receptor LOX-1 resulting in an increased oxLDL uptake. Expression of plasminogen activator inhibitor-1 (PAI-1) is increased via AT1 receptor activation predisposing to a procoagulant state. The effects of angiotensin II on tissue plasminogen activator (tPA) are controversial.PerspectivesAtherosclerosis is clearly caused by both a genetic predisposition to the disease and a variety of exogenous risk factors. Whereas the epidemiological correlation between risk factors and atherosclerosis has been established, the molecular events initiated by those risk factors that ultimately lead to atherosclerosis remain poorly understood. It is apparent from the data accumulated to date, that one possible link between risk factors and the development of vascular disease is in fact AT1 receptor activation. AT1 receptor–evoked oxidative stress has been implicated in all states of atherosclerosis, starting with the development of endothelial dysfunction and ultimately leading to plaque rupture and occlusion of the diseased vessel. Besides the traditional effects of AT1 receptor activation, such as vasoconstriction, water and salt homeostasis, and neurohumoral activation, the interaction of the AT1 receptor with radical-producing systems such as the NAD(P)H oxidase and the eNOS enzyme is thought to be a key event in atherogenesis.AT1 receptor antagonists or ACE inhibitors normalize oxidative stress and endothelial dysfunction and reduce the progression of atherosclerosis.44–46 ACE inhibitors are known to retard the progression of atherosclerosis and heart failure.51–53 In men suffering from coronary heart disease, ACE inhibitors improve endothelial dysfunction and reduce rate of death from cardiovascular causes.54 Recent studies in hypertensive and atherosclerotic individuals showed that AT1 receptor antagonists improved endothelial dysfunction, suggesting that these drugs, like ACE inhibitors, benefit vascular function.45,46Thus, AT1 receptor–elicited oxidative stress has been identified as one key event of the atherosclerotic disease process. Therefore, ACE inhibitors as well as AT1 receptor antagonists are potent antiatherosclerotic drugs, which is predominately related to their antioxidative properties. However, large-scale investigations will have to show that AT1 receptor antagonists not only decrease free radicals and improve endothelial dysfunction but also inhibit atherosclerosis-associated mortality and morbidity.FootnotesCorrespondence to Dr Georg Nickenig, Klinik und Poliklinik Innere Medizin III, Universität des Saarlandes, 66421 Homburg/Saar, Germany. E-mail [email protected] References 1 Peach MJ. Renin-angiotensin system: biochemistry and mechanism of action. Physiol Rev. 1977; 57: 313–370.CrossrefMedlineGoogle Scholar2 Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993; 87: 1816–1828.CrossrefMedlineGoogle Scholar3 Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993; 45: 205–251.MedlineGoogle Scholar4 Griendling KK, Lassègue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol. 1996; 36: 281–306.CrossrefMedlineGoogle Scholar5 Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–126.CrossrefMedlineGoogle Scholar6 Vaughan DE. AT1 receptor blockade, and atherosclerosis, hopeful insights into vascular protection. Circulation. 2000; 101: 1496–1497.CrossrefMedlineGoogle Scholar7 Strawn WB, Dean RH, Ferrario CM. Novel mechanisms linking angiotensin II and early atherogenesis. JRAAS. 2000; 1: 11–17.Google Scholar8 Unger T. The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens. 1999; 17: 1775–1786.CrossrefMedlineGoogle Scholar9 Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000; 35: 155–163.CrossrefMedlineGoogle Scholar10 Mallat Z, Tedgui A. Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol. 2000; 130: 947–962.CrossrefMedlineGoogle Scholar11 Lemay J, Hamet P, de Blois D. Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury. JRAAS. 2000; 1: 46–50.Google Scholar12 Dzau VJ. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J. 1998; 19: J2–J6.MedlineGoogle Scholar13 Romero JC, Reckelhoff JF. State-of-the-art lecture: role of angiotensin and oxidative stress in essential hypertension. Hypertension. 1999; 34: 943–949.CrossrefMedlineGoogle Scholar14 Babior BM. Phagocytes and oxidative stress. Am J Med. 2000; 109: 33–44.CrossrefMedlineGoogle Scholar15 Hensley K, Robinson KA, Gabbita SP, et al. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med. 2000; 28: 1456–1462.CrossrefMedlineGoogle Scholar16 Griendling KK, Harrison DG. Dual role of reactive oxygen species in vascular growth. Circ Res. 1999; 85: 562–563.CrossrefMedlineGoogle Scholar17 Harrison DG. Endothelial function and oxidant stress. Clin Cardiol. 1997; 20 (suppl II): 11–17.MedlineGoogle Scholar18 Patel RP, Moellering D, Murphy-Ullrich J, et al. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med. 2000; 28: 1780–1794.CrossrefMedlineGoogle Scholar19 Pueyo ME, Gonzalez W, Nicoletti A, et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol. 2000; 20: 645–651.CrossrefMedlineGoogle Scholar20 Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation. 2000; 101: 305–310.CrossrefMedlineGoogle Scholar21 Luft FC, Mervaala E, Muller DN, et al. Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension. 1999; 33: 212–218.CrossrefMedlineGoogle Scholar22 Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 2001; 280: C53–C60.CrossrefMedlineGoogle Scholar23 Janiszewski M, Pasqualucci CA, Souza LC, et al. Oxidized thiols markedly amplify the vascular response to balloon injury in rabbits through a redox active metal-dependent pathway. Cardiovasc Res. 1998; 39: 327–338.CrossrefMedlineGoogle Scholar24 Funck RC, Wilke A, Rupp H, et al. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol. 1997; 432: 35–44.CrossrefMedlineGoogle Scholar25 Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells. Circ Res. 1994; 74: 1141–1148.CrossrefMedlineGoogle Scholar26 Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000; 86: 494–501.CrossrefMedlineGoogle Scholar27 Suh YA, Arnold RS, Lassegue B, et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature. 1999; 401: 79–82.CrossrefMedlineGoogle Scholar28 Meyer JW, Schmitt ME. A central role for the endothelial NAD(P)H oxidase in atherosclerosis. FEBS Lett. 2000; 472: 1–4.CrossrefMedlineGoogle Scholar29 Griendling KK, Sorescu D, Lassegue B, et al. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000; 20: 2175–2183.CrossrefMedlineGoogle Scholar30 Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1-receptor expression an rac1 GTPase. Mol Pharmacol. 2001; 59: 646–654.CrossrefMedlineGoogle Scholar31 Wang W, Wang S, Yan L, et al. Superoxide production and reactive oxygen species signaling by endothelial nitric-oxide synthase. J Biol Chem. 2000; 275: 16899–16903.CrossrefMedlineGoogle Scholar32 Shinozaki K, Nishio Y, Okamura T, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res. 2000; 87: 566–573.CrossrefMedlineGoogle Scholar33 Shinozaki K, Kashiwagi A, Nishio Y, et al. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta. Diabetes. 1999; 48: 2437–2445.CrossrefMedlineGoogle Scholar34 Xia Y, Tsai AL, Berka V, et al. Superoxide generation from endothelial nitric-oxide synthase: a Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem. 1998; 273: 25804–25808.CrossrefMedlineGoogle Scholar35 Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 1998; 95: 9220–9225.CrossrefMedlineGoogle Scholar36 Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001; 88: e14–e22.CrossrefMedlineGoogle Scholar37 Hsieh HJ, Cheng CC, Wu ST, et al. Increase of reactive oxygen species in endothelial (ROS) cells by shear flow and involvement of ROS in shear-induced c-fos expression. J Cell Physiol. 1998; 175: 156–162.CrossrefMedlineGoogle Scholar38 Abe J, Berk BC. Fyn and JAK2 mediate RAS activation by reactive oxygen species. J Biol Chem. 1999; 274: 21003–21010.CrossrefMedlineGoogle Scholar39 Kawakami M, Okabe E. Superoxide anion radical-triggered Ca2+ release from cardiac sarcoplasmatic reticulum through ryanodine receptor Ca2+ channel. Mol Pharmacol. 1998; 53: 497–503.CrossrefMedlineGoogle Scholar40 Ushio-Fukai M, Wayne Alexander R, Akers M, et al. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. J Biol Chem. 1998; 273: 15022–15029.CrossrefMedlineGoogle Scholar41 Ushio-Fukai M, Alexander WR, Akers M, et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem. 1999; 274: 22699–22704.CrossrefMedlineGoogle Scholar42 Tomasian D, Keaney JF, Vita JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovasc Res. 2000; 47: 426–435.CrossrefMedlineGoogle Scholar43 Laursen JB, Rajagopalan S, Galis Z, et al. Role of superoxide in angiotensin II–induced but not catecholamine-induced hypertension. Circulation. 1997; 95: 588–593.CrossrefMedlineGoogle Scholar44 Mancini JGB, Henry GC, Macaya C, et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial dysfunction in patients with coronary artery disease. Circulation. 1996; 94: 258–265.CrossrefMedlineGoogle Scholar45 Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000; 101: 2349–2354.CrossrefMedlineGoogle Scholar46 Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000; 101: 1653–1659.CrossrefMedlineGoogle Scholar47 Kranzhöfer R, Browatzki M, Schmidt J, et al. Angiotensin II activates the proinflammatory transcription factor nuclear factor-κB in human monocytes. Biochem Biophys Res Commun. 1999; 257: 826–828.CrossrefMedlineGoogle Scholar48 Morawietz H, Rueckschloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation. 1999; 100: 899–902.CrossrefMedlineGoogle Scholar49 Keidar S, Attias J. Angiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathway. Biochem Biophys Res Commun. 1997; 239: 63–67.CrossrefMedlineGoogle Scholar50 Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000; 101: 1372–1378.CrossrefMedlineGoogle Scholar51 Pitt B. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol. 1997; 79: 24–28.Google Scholar52 Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342: 821–828.MedlineGoogle Scholar53 Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med. 1987; 316: 1429–1435.CrossrefMedlineGoogle Scholar54 Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme, ramipril, on cardiovascular events. N Engl J Med. 2000; 342: 145–153.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Sanz B, Rezola-Pardo C, Arrieta H, Fernández-Atutxa A, Lora-Diaz I, Gil-Goikouria J, Rodriguez-Larrad A and Irazusta J (2022) High serum angiotensin-converting enzyme 2 activity as a biomarker of frailty in nursing home residents, Experimental Gerontology, 10.1016/j.exger.2021.111655, 158, (111655), Online publication date: 1-Feb-2022. Zhang L, Zhang Y, Qin X, Jiang X, Zhang J, Mao L, Jiang Z, Jiang Y, Liu G, Qiu J, Chen C, Qiu F and Zou Z (2022) Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein, Critical Care, 10.1186/s13054-022-04034-9, 26:1, Online publication date: 1-Dec-2022. Aghamiri S, Komlakh K and Ghaffari M (2022) The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy, Inflammopharmacology, 10.1007/s10787-021-00919-3, 30:1, (51-60), Online publication date: 1-Feb-2022. Hyun S, Bhilare K, In G, Park C and Kim J (2022) Effects of Panax ginseng and ginsenosides on oxidative stress and cardiovascular diseases: pharmacological and therapeutic roles, Journal of Ginseng Research, 10.1016/j.jgr.2021.07.007, 46:1, (33-38), Online publication date: 1-Jan-2022. Brasil T, Belém-Filho I, Fortaleza E, Antunes-Rodrigues J and Corrêa F (2021) The AT-1 Angiotensin Receptor is Involved in the Autonomic and Neuroendocrine Responses to Acute Restraint Stress in Male Rats, Cellular and Molecular Neurobiology, 10.1007/s10571-021-01090-7, 42:1, (109-124), Online publication date: 1-Jan-2022. Roy S and Ghanta D (2021) A CLINICAL STUDY SHOWING ASSOCIATION OF SERUM LIPIDS WITH PRIMARY OPEN ANGLE GLAUCOMA, INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, 10.36106/4802037, (63-64), Online publication date: 1-Mar-2021. Zhao M, Yuan S, Zi H, Gu J, Fang C, Zeng X and Liu Y (2021) Oxidative Stress Links Aging-Associated Cardiovascular Diseases and Prostatic Diseases, Oxidative Medicine and Cellular Longevity, 10.1155/2021/5896136, 2021, (1-12), Online publication date: 17-Jul-2021. Chen L, Wang L, Shu G and Li J (2021) Antihypertensive Potential of Plant Foods: Research Progress and Prospect of Plant-Derived Angiotensin-Converting Enzyme Inhibition Compounds, Journal of Agricultural and Food Chemistry, 10.1021/acs.jafc.1c02117, 69:18, (5297-5305), Online publication date: 12-May-2021. Toth P (2021) Inflammation and Atherosclerotic Cardiovascular Disease ASPC Manual of Preventive Cardiology, 10.1007/978-3-030-56279-3_14, (289-333), . Liu C, Li X, Fu J, Chen K, Liao Q, Wang J, Chen C, Luo H, Jose P, Yang Y, Yang J and Zeng C (2021) Increased AT1 receptor expression mediates vasoconstriction leading to hypertension in Snx1−/− mice, Hypertension Research, 10.1038/s41440-021-00661-x, 44:8, (906-917), Online publication date: 1-Aug-2021. Elcik D, Kelesoglu S, Yilmaz Y, Cetinkaya Z, Sulaiman J, Yurt R, Neselioglu S, Erel O, Inanc M and Oguzhan A (2021) Relationship between thiol, disulphide volume and contrast-induced nephropathy in acute coronary syndrome patients treated with percutaneous coronary intervention, Scandinavian Journal of Clinical and Laboratory Investigation, 10.1080/00365513.2021.1878386, 81:3, (173-180), Online publication date: 3-May-2021. Love K and Liu Z (2021) DPP4 Activity, Hyperinsulinemia, and Atherosclerosis, The Journal of Clinical Endocrinology & Metabolism, 10.1210/clinem/dgab078, 106:6, (1553-1565), Online publication date: 13-Ma
Referência(s)